Myelofibrosis: Treatment Options After Ruxolitinib Failure
While allogeneic hematopoietic stem cell transplantation remains the only curative therapy for patients with myelofibrosis, its applicability is limited both by the high morbidity and mortality associated with the procedure and by the fact that only a minority of patients are eligible due to age or...
Saved in:
Main Authors: | Ruth Stuckey, Adrián Segura Díaz, María Teresa Gómez-Casares |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/32/6/339 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01) -
Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01) -
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01) -
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01) -
Possibilities of targeted therapy for myelofibrosis: Moscow experience
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01)